The Basics of Bacteriuria: Strategies of Microbes for Persistence in Urine

Deepak S. Ipe, Ella Horton and Glen C. Ulett*

School of Medical Science, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia

Bacteriuria, the presence of bacteria in urine, is associated with asymptomatic, as well as symptomatic, urinary tract infection (UTI). Bacteriuria underpins some of the dynamics of microbial colonization of the urinary tract, and probably impacts the progression and persistence of infection in some individuals. Recent molecular discoveries in vitro have elucidated how some key bacterial traits can enable organisms to survive and grow in human urine as a means of microbial fitness adaptation for UTI. Several microbial characteristics that confer bacteruric potential have been identified including de novo synthesis of guanine, relative resistance to D-serine, and catabolism of malic acid. Microbial characteristics such as these are increasingly being defined through the use of synthetic human urine (SHU) in vitro as a model to mimic the in vivo environment that bacteria encounter in the bladder. There is considerable variation in the SHU model systems that have been used to study bacteriuria to date, and this influences the utility of these models. In this review, we discuss recent advances in our understanding of bacteruric potential with a focus on the specific mechanisms underlying traits that promote the growth of bacteria in urine. We also review the application of SHU in research studies modeling UTI and discuss the chemical makeup, and benefits and limitations that are encountered in utilizing SHU to study bacterial growth in urine in vitro.

Keywords: bacteriuria, asymptomatic bacteriuria, urinary tract infection, urine, urinalysis, uropathogen, synthetic human urine, artificial urine

INTRODUCTION: BACTERIURIA AND URINARY TRACT INFECTION

“Asymptomatic Bacteriuria” (ABU or ASB) is synonymous with asymptomatic Urinary Tract Infection (UTI) in defining the isolation of a specified semi-quantitative count of bacteria in an appropriately collected urine specimen from a person without signs or symptoms related to UTI (Rubin et al., 1992; Nicolle et al., 2005). Bacteriuria is a marker for symptomatic UTI (sUTI) and assists in grading the severity of infection. Establishment of bacteriuria depends on entry of an organism with bacteruric potential into the urinary tract and can persist for months or years. Bacteruric potential encompasses microbial survival, growth, and re-growth in urine, and endurance of host defense mechanisms including dilution, voiding, frequent flushing (O’grady and Cattell, 1966a,b), and antimicrobial constituents such as Tamm-Horsfall glycoprotein (aka uromodulin), and P blood group antigen (Hand et al., 1971; Lomberg et al., 1983; Bates et al., 2004). Bacteruric potential can thus influence the persistence of ABU and sUTI. Here, we analyze the differences in microbial strategies used for growth in urine and the methods for modeling bacteriuria using synthetic human urine (SHU).
MICROBIAL BACTERURIC POTENTIAL AND HOST DYNAMICS

Recent reviews have focused on the pathogenesis of acute sUTI (Niélubowicz and Mobley, 2010; Hanan et al., 2012; Ulett et al., 2013), and ABU (Ipe et al., 2013; Schneeberger et al., 2014) and will not be revisited here. We will focus on bacteriuria specifically; the progression of which depends on microbe traits as well as host factors. Most individuals who suffer persistent UTI do not harbor the same strain of organism over time (Hooton et al., 2000), implying that turnover of causal organisms is dynamic. Replacement of colonizing strains during bacteriuria has been studied for *Escherichia coli*, the most common cause of ABU (Ipe et al., 2013). Long-term bacteriuria appears to select for attenuated virulence phenotypes of colonizing strains (Salvador et al., 2012). While most microbes are killed by urine, different organisms have distinct bacteruric potential. Several traits can affect microbial growth in urine. Antibiotics stop the progression of bacteriuria (Schneeberger et al., 2012) but patients infected with *E. coli* experience re-colonization with the same or similar organism at high rates (Dalal et al., 2009). This highlights the dynamic nature of bacteriuria and the role of therapeutic intervention [that is not recommended as routine for ABU (Nicolle, 2014)]. Other factors that are associated with the promotion of long-term bacteriuria are defects in immune signaling pathways such as TLRs (Ragnarsdóttir and Svanborg, 2012). Thus, persistence of bacteriuria relates to microbial bacteruric potential and host characteristics/dynamics including genetic immunodeficiency, re-current infection or strain replacement, and antibiotic therapy.

Microbial Metabolism and Growth Fitness in Urine: Knowledge from *E. coli*

The progression of bacteriuria depends on a microbes’ ability to survive the antimicrobial properties of urine. Urine survival and growth maintains a pool of colonizing organisms regardless of adherence to host cells, and urodynamic properties (urine flow rates, voiding) that differ between individuals (Wullt et al., 1998). Non-voided organisms in residual urine can grow and re-grow to maintain infection. Discoveries using ABU microbes have shaped our understanding of how bacteriuria progresses. ABU *E. coli* strain 83972 displays robust fitness for urine growth (Klemm et al., 2006; Roos et al., 2006b) though this is not a defining feature of all ABU *E. coli*, and is observed in some uropathogenic *E. coli* (UPEC) (Stamey and Mihara, 1980; Alteri and Mobley, 2007; Alteri et al., 2009; Aubron et al., 2012). Poor urine growth has been reported for some fecal *E. coli* isolates (Stamey and Mihara, 1980; Gordon and Riley, 1992). ABU *E. coli* 83972 has been investigated as a prophylactic means to treat acute sUTI (Hull et al., 2000; Wullt, 2003; Roos et al., 2006a; Sundén et al., 2006; Klemm et al., 2007; Watts et al., 2012a). The metabolic basis for urine growth of ABU *E. coli* 83972 involves transport and degradation pathways for galacturonate, glucuronide and galactonate (Roos et al., 2006b), and antioxidant defense mechanisms (Aubron et al., 2012); the details are described elsewhere (Roos et al., 2006a,b). More recently, analysis of ABU *E. coli* 83972 re-isolates indicated marked versatility of metabolic pathways in urine, including utilization of amino acids, hexuronates or (deoxy-) ribonucleosides as an adaptation to individual hosts (Zdziarski et al., 2010). This underlines the metabolic versatility of *E. coli* in urine in response to host-specific metabolic constraints. *guaA* and *argC* were shown to be critical for urine growth and a lack of urinary guanine (or derivatives), combined with an inability of *E. coli* to synthesize these compounds *de novo*, prevents the synthesis of other guanine (or derivative)-dependent products that are required for growth (Russo et al., 1996). Separate from guanine, *argC* and *carAB* mutants had reduced growth in urine in a *E. coli* transposon mutagenesis study, illustrating a role for arginine metabolism (Vejborg et al., 2012).

Knowledge from Bacteria other than *E. coli*

Clinical isolates of *Enterococcus faecalis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Klebsiella pneumoniae*, *Staphylococcus saprophyticus*, and *Streptococcus agalactiae* have been shown to grow in human urine (Table 1). However, little is known about the mechanisms used by these organisms for urine growth. For *E. faecalis* there are some similarities to *E. coli*; *E. faecalis* expresses multiple virulence genes in urine (Shepard and Gilmore, 2002) including genes for iron transport (Vebo et al., 2010). Iron utilization mechanisms have been reported in urine growth assays with *E. coli* (Watts et al., 2012b). Limiting manganese may be important in restricting *E. faecalis* urine growth (Järvisalo et al., 1992; Low et al., 2003; Vebo et al., 2010). In contrast to activation of pathways described for *E. coli*, *E. faecalis* activates citrate and aspartate metabolic pathways, and represses glucose uptake (Vebo et al., 2010). Human urine contains more citrate than glucose (Shaykhutdinov et al., 2009; Wishart et al., 2009; Bouatra et al., 2013), which could promote growth of *E. faecalis*. However, human urine is highly variable in chemical constituency and different levels of components such as glucose may influence microbial growth; for example, glucosuria enhances growth of *E. coli*. *E. faecalis* also upregulated genes for utilization of sucrose (and perhaps fructose), another constituent of urine (Tasevska et al., 2005; Bouatra et al., 2013). Other *E. faecalis* genes thought to function in urine growth include those related to import of phosphorylated sugars and glyceral, N-acetyl glucosamine metabolism (Vebo et al., 2010), cysteine synthase, and pathways for conversion of aspartate and α-ketoglutarate to oxaloacetate and glutamate. Urinary aspartate may be used for nitrogen metabolism (Guo and Li, 2009). *E. faecalis* is auxotrophic for multiple amino acids but human urine contains several amino acids including arginine, glutamate, glycine, and leucine (Guo and Li, 2009; Bouatra et al., 2013).

An analysis of metabolic traits of *P. aeruginosa* using synthetic urine revealed adaptation in central metabolism to lactate, citrate, and amino acids as carbon sources, and the induction of amino acid utilization pathways (Tielen et al., 2013). Metabolic flux analysis showed the use of the Entner-Doudoroff pathway with respiratory metabolism, with the pentose phosphate pathway being used exclusively for biosynthesis. Flux through pyruvate metabolism, the tricarboxylic acid cycle, and the glyoxylate shunt was highly variable, and likely caused by adaptive processes in individual strains during infection (Berger et al., 2014).
TABLE 1 | Summary of traits that contribute to bacteruric potential in microbes.

| Trait that confers bacteruric potential | Bacterial species | References |
|----------------------------------------|------------------|------------|
| Ability to utilize human urine as a substrate for growth | *E. coli* | Gordon and Riley, 1992; Russo et al., 1996; Roesch et al., 2003; Snyder et al., 2004; Johnson et al., 2006; Roos et al., 2006a; Alteri and Mobley, 2007; Klemm et al., 2007; Aubron et al., 2012; Vejborg et al., 2012; Watts et al., 2012b; Hryckowian et al., 2015; King et al., 2015; Shields-Cutler et al., 2015 |
| Tolerance to high levels of D-serine | *S. saprophyticus* | Sakinç et al., 2009 |
| Requirement for dsda for rapid urine growth | *E. coli* | Hryckowian et al., 2015 |
| Capacity for synthesis of guanine-dependent products critical for survival in urine | *E. coli* | Russo et al., 1996 |
| Expression of iron acquisition systems for growth in nutrient limiting environment | *E. coli* | Alteri and Mobley, 2007; Watts et al., 2012b; Shields-Cutler et al., 2015 |
| Osmoadaption, and intracellular accumulation of glycine betaine | *E. coli* | Vebo et al., 2010 |
| Adaptation of central metabolism to lactate, citrate and amino acids as carbon sources; flux through pyruvate metabolism, TCA cycle | *P. aeruginosa* | Tielen et al., 2013; Berger et al., 2014 |
| Malic acid metabolism | *S. agalactiae* | Ipe et al., 2016 |

Phenotype metabolic arrays were recently reported for ABU *S. agalactiae* (Ipe et al., 2016). Comparison with *S. agalactiae* strains that were unable to grow in urine showed that malic acid catabolism was important for growth in urine. Malic acid utilization is related to the malic enzyme metabolic pathway that catalyzes the oxidative decarboxylation of malate (a component of human urine depending on diet) to pyruvate and CO₂. This is related to malolactic fermentation, a bacterial metabolic process typically associated with wine deacidification (Landete et al., 2010).

Three Ways to Survive in Urine: Resistance, Acquisition, and Osmoadaption

Urine is naturally antimicrobial; hypertonicity with low pH (averaging ∼6.0) and high concentrations of urea inhibit most bacteria (Chambers and Lever, 1996; Kucharía et al., 2005). Nitrite in mildly acidified urine inhibits the growth of some uropathogens (Carlsson et al., 2001), and other abundant proteins such as Tamm-Horsfall glycoprotein are antimicrobial (Raffi et al., 2005; Säemann et al., 2005). Recently, the antimicrobial properties of urine were shown to include specific inhibition of both expression and function of UPEC type 1 pili (Greene et al., 2015), and downregulation of capsule genes (King et al., 2015). Individualistic urinary chemical features can also affect the antimicrobial properties of some antimicrobial urinary proteins such as siderocalin (Shields-Cutler et al., 2015). Bacteria that can endure urine antimicrobial properties do so through various means; for example, *S. saprophyticus* tolerates high concentrations of D-serine, which is abundant in urine and bacteriostatic toward organisms that lack a D-serine deaminase (Cosloy and McFall, 1973; Hryckowian et al., 2015). Iron limitation and the presence iron chelators such as lactoferrin (Weinberg, 1978) compounds the problem of nutritional immunity for microbes (Hood and Skaar, 2012) especially during states of increased iron chelator production (Gonzalez-Chavez et al., 2009; Soler-Garcia et al., 2009). Siderophores confer bacteruric potential to *E. coli* (Häversen et al., 2000; Snyder et al., 2004; Alteri and Mobley, 2007; Hagan and Mobley, 2009; Garcia et al., 2011; Watts et al., 2012b) and several genes encoding factors involved in iron transport are upregulated in *E. fecalis* during urine growth (Vebo et al., 2010). Siderophores may also act as ligands for cations other than iron, such as copper (Chaturvedi et al., 2012). Variable resistance to urinary defense molecules (e.g., nitrite, ascorbic acid) could influence bacteruric potential but little is known beyond the effects of these toward the chemical properties of urine (Carlsson et al., 2001). Finally, many organisms are probably unable to survive the oxygen concentrations encountered in the bladder (Leonhardt and Landes, 1963; Clarke et al., 1985).

Urea is abundant in urine and is antibacterial (Sobel, 1985). Osmoadaptive systems enable some bacteria to survive the stressful hypertonic conditions of urine. Bacterial accumulation of osmotically compatible solutes that are present in urine (e.g., betaines) confers bacteruric potential by effectively enabling microbes to resist dehydration (Chambers and Lever, 1996; Deutch et al., 2006). Osmoadaptive systems respond to changes in toxicity in urine, and support survival by counteracting low pH, high urea concentrations and hypertonicity (Chambers and Lever, 1996). For *E. coli*, glycine betaine is a central osmoprotectant to resist urea toxicity, and its accumulation is essential to adaptive responses to osmotic stress (Kunin et al.,
1992; Chambers and Lever, 1996). *E. coli* increases the activity of potassium transport systems that encompass TrkG, TrkH, and Kdp (Meury et al., 1985), or Kdp (Laimins et al., 1978) to counteract osmotic stress. Other systems involve trehalose as an organic osmolyte; its induction is triggered in conditions of high potassium (and glutamate) (Strom and Kaasen, 1993), and its accumulation elicits the release of potassium from the cell (Dinnbier et al., 1988). This might aid growth since trehalose can be used as a carbon source (Gutierrez et al., 1989; Styrvold and Strom, 1991). OmpR regulates osmoadaptive genes in *E. coli* (Barron et al., 1986). Osmotic stress suppresses the expression of fimbriae and flagellin (Kunin et al., 1994, 1995). Future studies of bacteria other than *E. coli* that can grow in urine will elucidate additional mechanisms of resistance to urinary antimicrobial properties, nutrient acquisition and metabolism, and osmoadaptation.

**Between a Rock and a Hard-Place: The Bladder Mucosa–Lumen Interface of Immune Surveillance and Bacteriuria**

Inflammation is a critical part of sUTI pathogenesis (Hannan et al., 2012; Ulett et al., 2013) and involves thousands of genes that drive antibacterial responses within hours of infection (Duell et al., 2012; Tan et al., 2012; Carey et al., 2016). For example, antimicrobial peptides produced by the bladder are important for protection against infection (Chromek et al., 2006). Microbes must survive these inflammatory events. Urine is a “Hard-place” for microbes to survive, as discussed above. Tissue inflammation in the bladder represents a “rock” of antimicrobial responses for defense against UTI and, for ABU, can encompass pyuria, cytokine release (IL-1α, -6, and -8), and antibody production, which has been documented in elderly adults, as reviewed elsewhere (Nicolle, 1997). Excessive inflammation may contribute to chronic sUTI (Hannan et al., 2010) and some acute sUTI symptoms have been linked to specific inflammatory events (Rudick et al., 2010). However, the benign, minimally inflammatory nature of ABU is reflected in the lack of morbidity in individuals who do not receive therapy (Nicolle, 1997, 1999; Ariathianto, 2011). Details of how ABU bacteria induce and minimize inflammation offer insight into how microbial modulation of host defense may promote bacteriuria. ABU *E. coli* minimizes inflammation by averting adherence due to a lack of fimbrae expression; this limits immune activation (Roos et al., 2006b) and results in long-term ABU (Arthur et al., 1989; Andersson et al., 1991). Grönberg-Hernandez et al. showed that ABU *E. coli* activates IRF3 and TLR4-dependent signaling, however, triggering a response that depends on host genetic background (Grönberg-Hernández et al., 2011); the IRF3-dependent signaling pathway is critical for distinguishing pathogens from the normal flora (Fischer et al., 2010). TLR4 senses P-fimbriated *E. coli* (Frendéus et al., 2001), and TLR4 mutations may favor ABU by impeding innate responses (Svanborg et al., 2006). This raises the question of whether ABU may influence subsequent encounter(s) with other uropathogens. One study on streptococcal UTI showed an influence on the severity of subsequent *E. coli* UTI in mice (Kline et al., 2012). Thus, immune activation triggered by ABU might affect subsequent sUTI caused by diverse pathogens. These data offer some parallel to clinical observations that patients with *E. coli* ABU suffer re-colonization at high rates following therapy (Dalal et al., 2009).

**MODELING BACTERIURIA IN VITRO: SYNTHETIC HUMAN URINE (SHU)**

Urine is unique from a microbial perspective and its chemical makeup, distinct from all other bodily fluids, has been modeled for studying the growth of microbes for 50 years (O’grady and Pennington, 1966). Urine has a low pH and a high osmolality due to the presence of salts and urea (Kucheria et al., 2005; Sheewin, 2011). The peptides, proteins, and organic acids present in urine may be metabolized by microbes (Decramer et al., 2008). Urine is dynamic in flow rate and composition, which changes subject to diet, age, gender and health status, and disease. Decreased levels of THP, for example, are associated with diabetes (Torffvit and Agardh, 1993) and infection (Ronald and Ludwig, 2001). Data on microbial traits that afford bactericidal potential have, in many cases, been derived from studies using SHU. Eight original SHU media recipes were described between 1971 and 2010: as summarized according to research application and composition in Table 2.

SHU offers several advantages compared to normal human urine collected from healthy adults for research assays *ex vivo*; it avoids the issue of variable chemical composition encountered with fresh human urine; variation in urinary constituents between individuals (Bouatra et al., 2013) is a challenge for standardizing research studies. Methods for “normalizing” fresh human urine include pooling samples and adjusting dilution/concentration according to creatinine concentration, specific gravity, and osmolality. The most widely used method is creatinine adjustment (Barr et al., 2005), however no bacteriuria research studies to date have applied these methods for normalizing, and the effects on data interpretation are unknown. Volume limits have been difficult for some studies (Davis et al., 1982). As a surrogate model, the benefits of SHU are defined by how closely it can reflect the chemical complexity of fresh human urine. Urine from a healthy adult contains glucose (0.2–0.6 mM) (Shaykhutdinov et al., 2009), creatine (0.38–55.6 mM; Barr et al., 2005; Shaykhutdinov et al., 2009), and glycine with low levels of other amino acids such as D-serine (Huang et al., 1998; Pätzold et al., 2005), histidine, glutamine, methionine, proline, glutamate, arginine, cysteine, and branched chain amino acids (Guo and Li, 2009; Vebø et al., 2010). It contains trace fatty acids, citrate (1.0–2.0 mM) (Wis hart et al., 2009), sucrose (70–200 μM) (Tasevská et al., 2005), and manganese (nM range) (Jarvisalo et al., 1992).

To standardize SHU composition for bacteriuria studies, we propose a composite SHU medium recipe (Table 2), and compare this to descriptions of “typical human urine” (Putnam et al., 1971; Bouatra et al., 2013). Examples of supplements to previously used SHU formulations include Lysogeny Broth (LB), Todd-Hewitt Broth (THB), and dextrose for fungi such as Candida sp. (Table 2). The proposed composite SHU
### TABLE 2 | Original and subsequent studies using Synthetic Human Urine (SHU) (A), and related SHU constituents, and proposed composite SHU (B).

| A. Original study | Focus of the research application | Microbes or cell types | Relevance | Reference(s) citing the original study |
|-------------------|-----------------------------------|------------------------|-----------|--------------------------------------|
| 1. Physiology (Aurora et al., 1980) | Understanding the development of calcium oxalate monohydrate precipitation | N/A | Urolithiasis | Mayrovitz and Sims, 2001 |
| 2. Infection (Brooks and Keevil, 1997) | Development of SHU to investigate the growth of urinary pathogens | *E. coli*, *P. aeruginosa*, *P. mirabilis*, *S. epidermidis*, *C. albicans* | UTI | Darouiche et al., 2008; Wernli et al., 2013; Azevedo et al., 2014; Lehman and Donlan, 2015; Wilks et al., 2015 |
| 3. Physiology (Burns and Finlayson, 1980) | Description of standard SHU for in vitro urolithiasis assays | N/A | Urolithiasis | Brown et al., 1989; Rodgers and Wandt, 1991; Opalko et al., 1997; Mayrovitz and Sims, 2001; Christmas et al., 2002; Isaacson, 1969; Barker et al., 1974; Rose, 1975; Miller et al., 1977; Doremus et al., 1978; Gardner and Doremus, 1978 |
| 4. Cell Biology (Chutipongtanate and Thongboonkerd, 2010) | Comparison of multiple SHU media, and study in epithelial cell culture assays | Kidney epithelial cells | Cell Biology | Davis et al., 1989, 1991; Martino et al., 2003; Dahoff et al., 2011; Phuengkham and Nasonogla, 2015; Cited by: Dømergue et al., 2005; Mabbit et al., 2009; Ong et al., 2009, 2010; Cited by: Watts et al., 2010; Jain et al., 2007; Cited by: Silva et al., 2010; Rane et al., 2014; Negri et al., 2015; Robertson et al., 1968 |
| 5. Infection and Physiology (Griffith et al., 1976) | Investigation of infection-induced urinary stones | *E. coli*, *P. aeruginosa*, *P. mirabilis*, *Citrobacter koseri*, *Proteus rettgeri*, *Providencia stuartii*, *Morganella morgani*, *Klebsiella oxytoca*, | UTI, and Urolithiasis | Griffith et al., 1976; Minuth et al., 1976; Gardner and Doremus, 1978; Minuth et al., 1976; Gardner and Doremus, 1978; Aurora et al., 1980; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| 6. Infection (Minuth et al., 1976) | Measurement of the antimicrobial efficacy of gentamicin in SHU | *E. coli*, *P. aeruginosa* | UTI | Mansouri and Darouiche, 2008; Sako et al., 2014 |
| 7. Physiology (Putnam et al., 1971) | Characterization of urinary constituents | N/A | General | No citations published |
| 8. Physiology (Gardner and Doremus, 1978) | Study of calcium oxalate crystallization | N/A | Urolithiasis | Robertson et al., 1981; Cited by: Robertson and Scarr, 1986 |

| B. Constituent | [n]| Mean Conc. (Range) | Composite | References Citing Constituent |
|----------------|----|---------------------|-----------|-------------------------------|
| NaCl           | 8/8 | 113.3 (54–231) mM   | 100 mM    | Griffith et al., 1976; Minuth et al., 1976; Gardner and Doremus, 1978; Aurora et al., 1980; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| Na₂SO₄         | 8/8 | 17.0 (9.0–155,800) mM | 17.0 mM   | Griffith et al., 1976; Minuth et al., 1976; Gardner and Doremus, 1978; Aurora et al., 1980; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| pH             | 7/8 | 6.0 (5.7–7.2)       | 5.5–6.0   | Griffith et al., 1976; Minuth et al., 1976; Gardner and Doremus, 1978; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| Urea           | 6/8 | 281 (170–500) mM    | 280 mM    | Griffith et al., 1976; Minuth et al., 1976; Gardner and Doremus, 1978; Aurora et al., 1980; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| KCl            | 6/8 | 58.5 (21.5–162.7) mM | 38.0 mM   | Griffith et al., 1976; Minuth et al., 1976; Aurora et al., 1980; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Chutipongtanate and Thongboonkerd, 2010 |
| CaCl₂          | 6/8 | 5.3 (2.5–12.0) mM   | 4.0 mM    | Griffith et al., 1976; Minuth et al., 1976; Burns and Finlayson, 1980; Robertson and Scarr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |

(Continued)
TABLE 2 | Continued

| Constituent     | (n) | Mean Conc. (Range) | Composite | References Citing Constituent |
|-----------------|-----|--------------------|-----------|------------------------------|
| Creatinine      | 5/8 | 8.7 (4.0–13.2) mM  | 9.0 mM    | Griffith et al., 1976; Minuth et al., 1976; Aurora et al., 1980; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| Na₂C₆H₅O₇       | 5/8 | 3.4 (2.2–6.0) mM  | 3.4 mM    | Griffith et al., 1976; Minuth et al., 1976; Burns and Finlayson, 1980; Robertson and Scurr, 1986; Chutipongtanate and Thongboonkerd, 2010 |
| NH₄Cl           | 5/8 | 36.6 (15.0–86.8) mM | 20.0 mM   | Griffith et al., 1976; Minuth et al., 1976; Robertson and Scurr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| MgSO₄           | 5/8 | 3.2 (2.0–6.9) mM  | 3.2 mM    | Aurora et al., 1980; Burns and Finlayson, 1980; Robertson and Scurr, 1986; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| Na₂C₂O₄         | 5/8 | 0.38 (0.1–1.2) mM | 0.18 mM   | Griffith et al., 1976; Minuth et al., 1976; Burns and Finlayson, 1980; Chutipongtanate and Thongboonkerd, 2010 |
| NaH₂PO₄         | 4/8 | 20.9 (3.6–43.6) mM | 3.6 mM    | Griffith et al., 1976; Minuth et al., 1976; Robertson and Scurr, 1986; Chutipongtanate and Thongboonkerd, 2010 |
| Na₂HPO₄         | 4/8 | 6.5 (6.1–186.8) mM | 6.5 mM    | Gardner and Doremus, 1978; Aurora et al., 1980; Robertson and Scurr, 1986; Chutipongtanate and Thongboonkerd, 2010 |
| KH₂PO₄          | 3/8 | 16.0 (7.0–20.6) mM | 16.0 mM   | Griffith et al., 1976; Minuth et al., 1976; Brooks and Keevil, 1997 |
| C₆H₄N₂O₃       | 3/8 | 0.6 (0.4–1.0) mM  | 0.6 mM    | Aurora et al., 1980; Brooks and Keevil, 1997; Chutipongtanate and Thongboonkerd, 2010 |
| NaHCO₃          | 2/8 | 13.5 (2.0–25.0) mM | 13.5 mM   | Griffith et al., 1976; Minuth et al., 1976; Chutipongtanate and Thongboonkerd, 2010 |
| MgCl₂·6H₂O      | 2/8 | 3.2 (3.2) mM      | 3.2 mM    | Minuth et al., 1976; Chutipongtanate and Thongboonkerd, 2010 |
| Osmolality      | 2/8 | 586 (446–725) mOsm/kg | 600 mOsm/kg | Griffith et al., 1976; Minuth et al., 1976; Robertson and Scurr, 1986; Chutipongtanate and Thongboonkerd, 2010 |
| C₆H₃O₇         | 2/8 | 1.7 (1.4–2.0) mM  | –         | Aurora et al., 1980; Brooks and Keevil, 1997 |
| TSB⁸           | 2/8 | 2.0% (1.0–5.0%) (v/v) | –         | Griffith et al., 1976; Minuth et al., 1976; Torzewski et al., 2003, 2014; Torzewski and Rózalski, 2014, 2015 |
| NH₃OH           | 1/8 | 17.1 mM           | –         | Aurora et al., 1980 |
| C₉H₉N₃O₄      | 1/8 | 2.8 mM            | –         | Aurora et al., 1980 |
| K₂HPO₄         | 1/8 | 7.0 mM            | –         | Brooks and Keevil, 1997 |
| C₃H₇O₃        | 1/8 | 1.1 mM            | 1.1 mM    | Brooks and Keevil, 1997 |
| FeSO₄·7H₂O     | 1/8 | 0.005 mM          | 0.005 mM  | Brooks and Keevil, 1997 |
| K₃C₂H₅O₇      | 1/8 | 2752000 mM        | –         | Gardner and Doremus, 1978 |
| Mg(NO₃)₂·6H₂O  | 1/8 | 2.5 mM            | –         | Gardner and Doremus, 1978 |
| Peptone⁸        | 1/8 | 0.1% (w/v)        | –         | Brooks and Keevil, 1997 |
| Yeast extract⁸ | 1/8 | 0.0005% (w/v)    | –         | Brooks and Keevil, 1997 |
| Glucose        | 0/8 | 1.0% (0.3–2.0%) (w/v) | –         | Uppuluri et al., 2009; Silva et al., 2010; Negri et al., 2012, 2015 |
| Sucrose        | 0/8 | 0.002% (w/v)     | –         | Wernli et al., 2013 |
| Lactose        | 0/8 | 0.002% (w/v)     | –         | Wernli et al., 2013 |
| LB⁸            | 0/8 | 3.5% (2.5–5.0%) (v/v) | –         | Domergue et al., 2005; Jain et al., 2007; Negri et al., 2011 |
| Dextrose⁸      | 0/8 | 3.4% (0.3–8.0%) (w/v) | –         | Domergue et al., 2005; Jain et al., 2007; Negri et al., 2011 |
| THB⁸           | 0/8 | 2.5% (v/v)       | –         | Ipe et al., 2016 |
| YNB³           | 0/8 | 5.0% (5.0–6.0%) (v/v) | –         | Jain et al., 2007; Uppuluri et al., 2009 |
| SC Broth⁸      | 0/8 | 5.0% (v/v)       | –         | Domergue et al., 2005 |

(Continued)
medium omits chemically undefined components such as LB to provide chemical definition, is easily prepared, inexpensive, and chemically stable. However, it is also not without its limitations; it excludes some natural constituents of human urine such as hormones, iron chelators, and pyrophosphates that could influence microbial growth. The relative concentrations of some urinary constituents differ between males and females (e.g., less calcium and oxalate, more citrate excretion in women, more creatinine in men; Ryall et al., 1987; Sarada and Satyanarayana, 1991; Bouatra et al., 2013) and the proposed composite SHU does not account for these differences. Nonetheless, as a balance between feasibility, logistics, and economy the proposed composite SHU medium should be of value to standardize future bacteriuria studies; importantly, studies will now need to validate the proposed composite SHU medium using a range of relevant bacteria, and in particular, analyze the need for supplements (e.g., yeast extract) to support the growth of fastidious organisms such as streptococci.

CONCLUSIONS AND FUTURE DIRECTIONS

A capacity of microorganisms for urine growth may aid in establishing long-term bacteriuria and is relevant to many microbial species. New discoveries on immune activation by microorganisms for urine growth in non-<i>E. coli</i> organisms; how ABU impacts on subsequent UTI including comparisons of immune responses to ABU caused by organisms other than <i>E. coli</i>. How effective ABU might be as a prophylactic approach against SUTI continues to be a topic for future investigation. More importantly, studies aimed at defining bacterial mechanisms that are critical for growth in urine are essential in the context of providing a foundation for novel treatment and preventive strategies.

REFERENCES

Alteri, C. J., and Mobley, H. L. (2007). Quantitative profile of the uropathogenic <i>Escherichia coli</i> outer membrane proteome during growth in human urine. <i>Infect. Immun.</i> 75, 2679–2688. doi: 10.1128/IAI.00676-06

Alteri, C. J., Smith, S. N., and Mobley, H. L. (2009). Fitness of <i>Escherichia coli</i> during urinary tract infection requires gluconeogenesis and the TCA cycle. <i>PLoS Pathog.</i> 5:e1000448. doi: 10.1371/journal.ppat.1000448

Acknowledgments

This work was supported by an Australian National Health and Medical Research Council (NHMRC) grant (APP1084889) (GU), and a Griffith University New Researcher Grant (219152) (DI). GU is supported by a Future Fellowship from the Australian Research Council (FT110101048).
Greene, S. E., Hibbing, M. E., Janetka, J., Chen, S. L., and Hultgren, S. J. (2015). Human urine decreases function and expression of Type 1 pili in uropathogenic *Escherichia coli*. *MBio* 6:e00820. doi: 10.1128/MBio.00820-15

Griffith, D. P., Musher, D. M., and Itin, C. (1976). Urease. The primary cause of infection-induced urinary stones. *Invest. Urol.* 13, 346–350.

Grönberg-Hernández, J., Sundén, F., Connolly, J., Svanborg, C., and Wullt, R. (2011). Genetic control of the variable innate immune response to asymptomatic bacteriuria. *PLoS ONE* 6:e28289. doi: 10.1371/journal.pone.0028289

Guo, K., and Li, L. (2009). Differential 12C-13C-isotope dancylation labeling and fast liquid chromatography/mass spectrometry for absolute and relative quantification of the metabolome. *Anal. Chem.* 81, 3919–3932. doi: 10.1021/ac90166a

Gutierrez, C., Ardourel, M., Bremer, E., Middendorf, A., Boos, W., and Ehmann, U. (1989). Analysis and DNA sequence of the osmoregulated treA gene encoding the periplasmic trelase of *Escherichia coli* K12. *Mol. Gen. Genet.* 217, 347–354. doi: 10.1007/BF02464963

Hagan, E. C., and Mobley, H. L. (2009). Haem acquisition is facilitated by a *Escherichia coli* utilization by asymptomatic bacteriuria.

Häversen, L. A., Engberg, I., Baltzer, L., Dolphin, G., Hanson, L. A., and Mattsby-Järvisalo, J., Olkinuora, M., Kiilunen, M., Kivistö, H., Ristola, P., Tossavainen, A., et al. (2011). Phenotypic heterogeneity in expression of the K1 polysaccharide capsule of uropathogenic *Escherichia coli* and downregulation of the capsule genes during growth in urine. *Infect. Immun.* 83, 2605–2613. doi: 10.1128/IAI.00188-15

Klemm, P., Hancock, V., and Schmeltz, M. A. (2007). Melling out: adaptation to commensalism by *Escherichia coli* asymptomatic bacteriuria strain 83972. *Infect. Immun.* 75, 3688–3695. doi: 10.1128/IAI.01730-06

Klemm, P., Roos, V., Ulett, G. C., Svanborg, C., and Schmeltz, M. A. (2006). Molecular characterization of the *Escherichia coli* asymptomatic bacteriuria strain 83972: the taming of a pathogen. *Infect. Immun.* 74, 781–785. doi: 10.1128/IAI.74.2.781-785.2006

Kline, K. A., Schwartz, D. J., Gilbert, N. M., Hultgren, S. J., and Lewis, A. L. (2012). Immune modulation by group B Streptococcus influences host susceptibility to urinary tract infection by uropathogenic *Escherichia coli*. *Infect. Immun.* 80, 4186–4194. doi: 10.1128/IAI00684-12

Kucherla, R., Dasgupta, P., Sacks, S. H., Khan, M. S., and Sheerin, N. S. (2005). Urinary tract infections: new insights into a common problem. *Postgrad. Med.* J. 81, 83–86. doi: 10.1136/pgmj.2004.023036

Kunin, C. M., Hua, T. H., and Baakalez, L. O. (1995). Effect of salicylate on expression of flagella by *Escherichia coli* and Proteus, Providencia, and Pseudomonas spp. *Infect. Immun.* 63, 1796–1799.

Kunin, C. M., Hua, T. H., Guerrett, R. L., and Baakalez, L. O. (1994). Effect of salicylate, bismuth, osmolytes, and tetracycline resistance on expression of fimbriae by *Escherichia coli*. *Infect. Immun.* 62, 2178–2186.

Kunin, C. M., Hua, T. H., Van Arsdale White, L., and Villarejo, M. (1992). Growth of *Escherichia coli* in human urine: role of salt tolerance and accumulation of glycine betaine. *J. Infect. Dis.* 166, 1311–1315. doi: 10.1093/infdis/166.13.1111

Laimins, L. A., Rhoads, D. B., Altendorf, K., and Epstein, W. (1978). Identification of the structural proteins of an ATP-driven potassium transport system in *Escherichia coli*. *Proc. Natl. Acad. Sci. U.S.A.* 75, 3216–3219. doi: 10.1073/pnas.75.7.3216

Landete, J. M., García-Haro, L., Blasco, A., Manzanares, P., Berbegal, C., Monedero, V., et al. (2010). Requirement of the *Lactobacillus casei* MaeKR two-component system for L-malic acid utilization via a malic enzyme pathway. *Appl. Environ. Microbiol.* 76, 84–95. doi: 10.1128/AEM.02145-09

La Rosa, S. L., Diep, D. B., Nes, I. F., and Brede, D. A. (2012). Construction and application of a luxABCDE reporter system for real-time monitoring of *Enterococcus faecalis* gene expression and growth. *Appl. Environ. Microbiol.* 78, 7003–7011. doi: 10.1128/AEM.02018-12

Lee, S. C., Hutchinson, J. M., Inn, K. G., and Thein, M. (1995). An intercomparison study of 237NP determination in artificial urine samples. *Health Phys.* 68, 350–358. doi: 10.1097/00004032-199503000-00007

Lehman, S. M., and Donlan, R. M. (2015). Bacteriophage-mediated control of a two-species biofilm formed by microorganisms causing catheter-associated urinary tract infections in an *in vitro* urinary catheter model. *Antimicrob. Agents Chemother.* 59, 1127–1137. doi: 10.1128/AAC.03786-14

Leonhardt, K. O., and Landes, R. R. (1963). Oxygen tension of the urine and renal structures. Preliminary report of clinical findings. *N. Engl. J. Med.* 269, 115–121. doi: 10.1056/NEJM19630718269031

Lomberg, H., Hanson, L. A., Jacobsson, B., Jodal, U., Leffler, H., and Edén, C. S. (1983). Correlation of P blood group, vesicoureteral reflux, and bacterial attachment in patients with recurrent pyelonephritis. *N. Engl. J. Med.* 308, 1189–1192. doi: 10.1056/NEJM198309010200002

Low, Y. L., Jakubowics, N. S., Flatman, J. C., Jenkinson, H. F., and Smith, A. W. (2003). Manganese-dependent regulation of the endocarditis-associated virulence factor EfaA of *Enterococcus faecalis*. *J. Med. Microbiol.* 52, 113–119. doi: 10.1099/jmm.0.05309-0

Mabbett, A. N., Ulett, G. C., Watts, R. E., Tree, J. J., Totsika, M., Ong, C. L., et al. (2009). Virulence properties of asymptomatic bacteriuria *Escherichia coli*. *Int. J. Med. Microbiol.* 299, 53–63. doi: 10.1016/j.ijmm.2008.06.003

Mansouri, M. D., and Darouiche, R. O. (2008). *In-vitro* activity and *in-vivo* efficacy of catheters impregnated with chloroxylenol and thymol against uropathogens. *Clin. Microbiol. Infect.* 14, 190–192. doi: 10.1111/j.1469-0691.2007.01894.x

Johnson, J. R., Clabots, C., and Rosen, H. (2006). Effect of inactivation of the global oxidative stress regulator oxyR on the colonization ability of *Escherichia coli* O1:K1:H7 in a mouse model of ascending urinary tract infection. *Infect. Immun.* 74, 461–468. doi: 10.1128/IAI.74.1.461-468.2006

King, J. E., Aal Owaif, H. A., Jia, J., and Roberts, I. S. (2015). Phenotypic heterogeneity in expression of the K1 polysaccharide capsule of uropathogenic *Escherichia coli* and downregulation of the capsule genes during growth in urine. *Infect. Immun.* 83, 2605–2613. doi: 10.1128/IAI.00188-15
Martino, P. D., Fursy, R., Bret, L., Sundararaju, B., and Phillips, R. S. (2003). Indole can act as an extracellular signal to regulate biofilm formation of Escherichia coli and other indole-producing bacteria. Can. J. Microbiol. 49, 443–449. doi: 10.1139/w03-056
Mayrovitz, H. N., and Sims, N. (2001). Biophysical effects of water and synthetic urine on skin. Adv. Skin Wound Care 14, 302–308. doi: 10.1097/00129334-20011100-00013
Meury, J., Robin, A., and Monnier-Champex, P. (1985). Turgor-controlled K+ fluxes and their pathways in Escherichia coli. Eur. J. Biochem. 151, 613–619. doi: 10.1111/j.1432-1033.1985.tb09148.x
Miller, J. D., Randolph, A. D., and Drach, G. W. (1977). Observations upon calcium oxalate crystallization kinetics in simulated urine. J. Urol. 117, 342–345.
Minuth, J. N., Musher, D. M., and Thorsteinsson, S. B. (1976). Inhibition of the antibacterial activity of gentamicin by urine. J. Infect. Dis. 133, 14–21. doi: 10.1093/infdis/133.1.14
Negri, M., Silva, S., Breda, D., Henriques, M., Azeredo, J., and Oliveira, R. (2015). Candida tropicalis biofilms: effect on urinary epithelial cells. Microb. Pathog. 53, 95–99. doi: 10.1016/j.micpath.2015.02.006
Negri, M., Silva, S., Capoci, I. R., Azeredo, J., and Henriques, M. (2015). Candida tropicalis biofilms: biomass, metabolic activity and secreted asparyl proteinase production. Mycopathologia. doi: 10.1007/s11046-015-9964-4 [Epub ahead of print]
Negri, M., Silva, S., Henriques, M., Azeredo, J., Svidzinski, T., and Oliveira, R. (2011). Candida tropicalis biofilms: artificial urine, urinary catheters and flow model. Medical Mycology 49, 739–747. doi: 10.3109/13693786.2011.56019
Nickel, J. C., Russeka, L., Wright, J. B., and Costerton, J. W. (1985). Tobraedmian resistance of Pseudomonas aeruginosa cells growing as a biofilm on urinary catheter material. Antimicrob. Agents Chemother. 27, 619–624. doi: 10.1128/AAC.27.4.619
Nicolle, L. E. (1997). Asymptomatic bacteriuria in the elderly. Infect. Dis. Clin. North Am. 11, 647–662. doi: 10.1016/S0891-5520(05)70378-0
Nicolle, L. E. (1999). Urinary infections in the elderly: symptomatic or asymptomatic? Int. J. Antimicrob. Agents 11, 265–268.
Nicolle, L. E. (2014). Asymptomatic bacteriuria. Curr. Opin. Infect. Dis. 27, 90–96. doi: 10.1097/QCO.000000000000019
Nicolle, L. E., Bradley, S., Colgan, R., Rice, J. C., Schaeffer, A., and Hooton, T. M. (2005). Infectious Diseases Society of America guidelines for the diagnosis and treatment of asymptomatic bacteriuria in adults. Clin. Infect. Dis. 40, 643–654. doi: 10.1086/427507
Niembowicz, G. R., and Mobley, H. L. (2010). Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7, 430–441. doi: 10.1038/nruro.2010.101
O'grady, F., and Cattell, W. R. (1966a). Kinetics of urinary tract infection I. Upper urinary tract. Br. J. Urol. 38, 149–155.
O'grady, F., and Cattell, W. R. (1966b). Kinetics of urinary tract infection. II. The lower urinary tract. Br. J. Urol. 38, 156–162
O'grady, F., and Pennington, J. H. (1966). Bacterial growth in an in vitro system simulating conditions in the urinary bladder. Br. J. Exp. Pathol. 47, 152–157.
Ong, C. L., Beatson, S. A., McEwan, A. G., and Schembri, M. A. (2009). Conjugal plasmid transfer and adhesion dynamics in an Escherichia coli biofilm. Appl. Environ. Microbiol. 75, 6783–6791. doi: 10.1128/AEM.00974-09
Ong, C. L., Beatson, S. A., Totiska, M., Forestier, C., McEwan, A. G., and Schembri, M. A. (2010). Molecular analysis of type 3 fimbrial genes from Escherichia coli, Klebsiella and Citrobacter species. BMC Microbiol. 10.183. doi: 10.1186/1471-2180-10-183
Opalko, F. J., Adair, J. H., and Khan, S. R. (1997). Heterogeneous nucleation of calcium oxalate trihydrate in artificial urine by constant composition. J. Cryst. Growth 181, 410–417. doi: 10.1016/S0022-0248(97)00222-4
Pätzold, R., Schieber, A., and Brückner, U. (2005). Gas chromatographic quantification of free D-amino acids in higher vertebrates. Biomed. Chromatogr. 19, 466–473. doi: 10.1002/bmc.515
Phuengkham, H., and Nasonkla, N. (2015). Development of antibacterial coating on silicone surface via chlorhexidine-loaded nanospheres. J. Mater. Sci. Mater. Med. 26, 678. doi: 10.1007/s10856-015-5418-2
Putnam, D. F., Company-West, M. D. A., Center, L. R., Aeronautics, U. S. N., and Administration, S. (1971). Composition and Concentrative Properties of Human Urine. Washington, DC: National Aeronautics and Space Administration.
antifungals on the growth of *Candida albicans* in urine. *J. Appl. Microbiol.* 115, 1186–1193. doi: 10.1111/jam.12306

Wilks, S. A., Fader, M. J., and Keevil, C. W. (2015). Novel insights into the *Proteus mirabilis* crystalline biofilm using real-time imaging. *PLoS ONE* 10:e0141711. doi: 10.1371/journal.pone.0141711

Wishart, D. S., Knox, C., Guo, A. C., Eisner, R., Young, N., Gautam, B., et al. (2009). HMDB: a knowledgebase for the human metabolome. *Nucleic Acids Res.* 37, D603–D610. doi: 10.1093/nar/gkn810

Wullt, B. (2003). The role of P fimbriae for *Escherichia coli* establishment and mucosal inflammation in the human urinary tract. *Int. J. Antimicrob. Agents* 21, 605–621. doi: 10.1016/S0924-8579(02)00328-X

Wullt, B., Connell, H., Röllano, P., Månsson, W., Colleen, S., and Svanborg, C. (1998). Urodynamic factors influence the duration of *Escherichia coli* bacteriuria in deliberately colonized cases. *J. Urol.* 159, 2057–2062. doi: 10.1016/S0022-5347(01)63246-4

Zdziarski, J., Brzuszkiewicz, E., Wullt, B., Liesegang, H., Biran, D., Voigt, B., et al. (2010). Host imprints on bacterial genomes–rapid, divergent evolution in individual patients. *PLoS Pathog.* 6:e1001078. doi: 10.1371/journal.ppat.1001078

**Conflict of Interest Statement:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2016 Ipe, Horton and Ulett. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.